Request an Appointment
Before making an appointment, please fax a copy of your most recent pathology report to 443-769-1205. Then, call 443-997-0400 to get set up in the Johns Hopkins system. Once you are in the system and have your records sent, you can contact our office below to set up an appointment:
The link between HPV and cervical cancer is bigger than the link between smoking and lung cancer."-Dr. Connie Trimble, in her TedX Talk, Kicking Cancer's Butt
Johns Hopkins Outpatient Center
The Johns Hopkins Outpatient Center is renamed the Levi Watkins, Jr., M.D., Outpatient Center, effective June 2023. Dr. Watkins was a pioneer in cardiac surgery and civil rights who died in 2015.
Green Spring Station
The Johns Hopkins Kimmel Cancer Center’s Medical Oncology practice at Green Spring Station in Lutherville, Maryland, opened its doors in a brand new, spacious facility on June 3, 2019. Located on the first floor of Pavilion III, the practice features programs in breast cancer, lymphoma, lung cancer, melanoma, ovarian cancer, gastrointestinal cancers, and genitourinary cancers.
Research and Clinical Trials
We are interested in how immune responses occur in the cervix. The focus of our translational research is on developing immune therapies for disease caused by human papillomavirus (HPV). HPV infection causes more cancers than any other virus in the world.
Cervical cancer is the most common cancer caused by HPV, and although we have known how to screen for it for over half a century, it remains the second most common cause of cancer death in women. Although the preventive vaccines are a public health milestone, they prevent HPV infections, but are not designed to make immune responses to treat HPV.
We are testing different strategies to make immune responses that could treat HPV disease.
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
Overview: This phase I trial is studying the side effects and best dose of vaccine therapy and to see how well it works when given with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia.